Key facts
- It has raised $14.0M across 4 recorded rounds; the latest was Seed Round ($475K) in Sep 2024.
- Notable investors include American Society of Nephrology, Stanko Barle, U.S. Department of Health and Human Services.
- US Kidney Research has filed 8 Form Ds with the SEC since 2020, most recently Jan 2025 ($475K sold).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for US Kidney Research
Funding rounds
4 roundsAbout US Kidney Research
Developer of waterless blood purification device designed to revolutionary innovation with the potential to replace traditional dialysis machines worldwide. The company's waterless blood purification technology represents a paradigm shift in the field, its mission is to finalize our flagship portable prototype, progress toward an implantable artificial kidney, and advance multiple related products currently in development, providing the healthcare industry with a visionary approach to medical advancements.
- Sector
- Healthcare
- HQ
- Roseville, CA, United States
- Founded
- 2015
- Employees
- 6
- Website
- uskidneyresearchcorp.com/
- Ownership
- Privately Held (backing)
US Kidney Research doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in US Kidney Research shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on US Kidney Research in its N-PORT filings yet. We sweep new filings monthly.